Advertisement
Advertisement
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
523.69
USDSponsored
-16.20
-3.00%
May 15, 15:59 UTC -4
Closed
After-Market
526.50
+2.81
+0.54%
MDGL Earnings Reports
Positive Surprise Ratio
MDGL beat 23 of 42 last estimates.
55%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$357.79M
/-$1.94
Implied change from Q1 26 (Revenue/ EPS)
+14.92%
/-40.31%
Implied change from Q2 25 (Revenue/ EPS)
+68.13%
/+2.11%
Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 06, 2026, MDGL reported earnings of -3.25 USD per share (EPS) for Q1 26, beating the estimate of -4.10 USD, resulting in a 20.92% surprise. Revenue reached 311.34 million, compared to an expected 306.78 million, with a 1.49% difference. The market reacted with a +7.42% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -1.94 USD, with revenue projected to reach 357.79 million USD, implying an decrease of -40.31% EPS, and increase of 14.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
May 13, 2026 For Q4 26
Estimate
-$24.25
Actual
$44.19
Surprise
+282.20%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.51
Actual
-$0.61
Surprise
-19.51%
Aquestive Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+49.96%
Altimmune, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.24
Actual
-$0.18
Surprise
+27.18%
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
Achieve Life Sciences, Inc.
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.19
Surprise
+39.59%
Karyopharm Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.45
Actual
-$1.24
Surprise
+14.90%
Journey Medical Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-1.14%
Avita Medical, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.28
Actual
-$0.35
Surprise
-22.55%
PolyPid Ltd. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.81%
FAQ
What were Madrigal Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$3.25, beating estimates by 20.92%, and revenue of $311.34M, 1.49% above expectations.
How did the market react to Madrigal Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 7.42%, changed from $502.47 before the earnings release to $539.73 the day after.
When is Madrigal Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Madrigal Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 13
analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$1.94 and revenue of $357.79M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement